IRIS+ Phase II Feasibility Study
Research type
Research Study
Full title
Improving the response of general practice to adult patients experiencing and perpetrating domestic violence and to their children. IRIS+ Phase II Feasibility Study
IRAS ID
256321
Contact name
Gene Feder
Contact email
Sponsor organisation
University of Bristol
Duration of Study in the UK
2 years, 3 months, 30 days
Research summary
The IRIS+ (Enhanced Identification and Referral to Improve Safety) stage II feasibility study is part of the REPROVIDE (Reaching Everyone Programme of Research on Violence in diverse Domestic Environments) Programme.
IRIS+ will expand our previous research showing that general practice staff can respond appropriately to women experiencing domestic abuse. It will assist general practice professionals in identifying, documenting, and referring female and male patients who may have experienced abuse as victims, perpetrators, or both. It will also support children who may have been exposed to abuse to specialist services and offering them appropriate support.
Phase I of the IRIS+ study successfully developed and piloted the feasibility of the IRIS+ intervention. IRIS+ Phase I was well received by general practice professionals and patients, but the process evaluation and discussion with stakeholders and our PPI groups has driven the formulation of added elements to the intervention. Our learning from Phase I of the IRIS+ pilot needs to be integrated into the intervention and re-tested for feasibility and acceptability in the next phase of IRIS+ (Stage II).
The revised intervention model incorporates enhanced and tailored training about domestic abuse and a referral pathway for survivors and perpetrators and their children. It also includes the release of a medical records prompts system and a dedicated online resource supporting the face to face training.
In Stage II, we propose to test the enhanced model in eight general practices in two sites: Bristol and south Wales. Stage II will include the assessment of the feasibility of the reconfigured IRIS+ model. Stage II will also include an exploratory assessment of cost-effectiveness of the reconfigured intervention with feasibility data and may include a value of information analysis to inform the decision the best course of action at the culmination of stage II (i.e. recommendation for direct NHS implementation or not).
REC name
London - Surrey Borders Research Ethics Committee
REC reference
19/LO/1132
Date of REC Opinion
16 Aug 2019
REC opinion
Further Information Favourable Opinion